Andrew J. Roth

Hirsch Honored With Addario Lectureship Award in Lung Cancer

It is known that the fertility of adolescent and young adult patients with cancer can be put at risk by treatments, but little research has been conducted looking at awareness, counseling and actions in this area.

Though many patients with cancer are offered chemotherapy as palliative care during end-of-life treatment, its benefit has not been well studied previously.

The hotspots were identified in the lower Mississippi Delta, west central region of Appalachia and northeastern North Carolina/southeastern Virginia.

The addition of docetaxel to standard hormonal therapy significantly improved survival among men with newly diagnosed, hormone-naïve advanced prostate cancer.

Pembrolizumab (Keytruda) elicited significantly better outcomes compared with ipilimumab (Yervoy) in a randomized phase 3 trial of patients with advanced melanoma.

A trial comparing frontline Keytruda (pembrolizumab) with Yervoy (ipilimumab) for the treatment of advanced melanoma has met its progression-free survival and overall survival endpoints.

First-line treatment with Tykerb and a taxane failed to improve progression-free survival versus Herceptin plus a taxane in patients with HER2-positive metastatic breast cancer.

Emmanuel S. Antonarakis explains data looking at AR-V7 and response to taxane therapy in men with metastatic castration-resistant prostate cancer.

Ixazomib, also known as MLN9708, met its primary endpoint of improving progression-free survival at an interim analysis of a phase 3 trial of relapsed or refractory multiple myeloma.

Ibrutinib becomes the first drug specifically approved for Waldenstrom's macroglobulinemia (WM), two months ahead of expectations.

In the past four months, the PD-1 inhibitors Opdivo (nivolumab) and Keytruda (pembrolizumab) have been approved for the treatment of advanced melanoma. Jeffery S. Weber, a senior member at Moffitt Cancer Center in Tampa, Fla., provides insight on what this means for treating patients.

The Food and Drug Administration approves Lynparza (olaparib) for the treatment of women with BRCA-positive advanced ovarian cancer.

The FDA has approved Cyramza (ramucirumab) in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer whose tumor has progressed during or following treatment with platinum-based chemotherapy.

Tasigna in combination with chemotherapy elicited a complete hematological remissions (CHR) in 87 percent of elderly patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia (Ph-positive ALL).

An early study in patients with Hodgkin lymphoma that had progressed on several lines of treatment found that the immunotherapy Keytruda (pembrolizumab) elicited a remarkable response.

In September, The Ohio State University Comprehensive Cancer Center, collaborating with the Department of Emergency Medicine, opened a fully integrated cancer emergency department at the new James Cancer Hospital to care for patients who develop emergencies caused by their cancers.